期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

非小细胞肺癌患者外周血MDSC的比例及意义 被引量：4

原文传递
导出
摘要 目的本实验研究非小细胞肺癌患者外周血骨髓源性抑制细胞（MDSC）的比例及意义。方法采用流式细胞术计算患者外周血MDSC所占白细胞的比例，分析治疗前后MDSC比例的变化及其与临床特征、C-反应蛋白之间的关系。结果与正常对照组相比，非小细胞肺癌患者外周血MDSC比例明显上升（P〈0．05）。手术及有效的化疗均能降低患者外周血MDSC比例（P〈0．05）；患者外周血MDSC水平与血清C-反应蛋白水平呈正相关，与临床分期相关（P〈0．05），而尚不能认为与年龄、性别、组织学类型相关（P〉0．05）。结论非小细胞肺癌患者外周血MDSC水平明显升高，可能参与形成患者的免疫抑制状态，且患者高水平的MDSC既受肿瘤细胞诱导，又与炎症有关。
作者 李亚东 刘瑞青 刘杰 李醒亚
机构地区 郑州大学第一附属医院 河南省肿瘤医院
出处 《中国实用医刊》 2013年第1期61-64,共4页 Chinese Journal of Practical Medicine
关键词 骨髓源性抑制细胞 非小细胞肺癌 C-反应蛋白
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献16

  • 1Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system[J]. Nat Rev immunol,2009,9(3) :162-174.
  • 2Nagaraj S, Gabn'lovich DI. Myeloid-derived suppressor cells in human cancer [J]. Cancer, 2010, 16(4) :348-353.
  • 3Yang R. CD80in immune suppression by mouse ovarian carcinoma-as- sociated Gr-1 + CDllb + myeloidcells [ J. Cancer Res, 2006,66 (3) :6807-6815.
  • 4Pan PY, Wang GX, Yin B, et al. Reversion of immune to tolerance in advanced malignancy:modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function [ J 1. Blood, 2008, 111 ( 1 ) :219-228.
  • 5Serafini P, Carbley R, Noonan KA, et al. High-dose granulocyte- macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells[J]. Cancer Res, 2004, 64(17) :6337-6343.
  • 6Bunt SK, Yang L, Sinha P, et al. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression[ J 1. Cancer Res, 2007, 67(20) :10019-10026.
  • 7Sinha P, Okoro C, Foell D, et al. Proinflammatory S100 proteins reg- ulate the accumulation of myeloid-derived suppressor cells[ J. J Im- munol, 2008, 181(7) :4666-4675.
  • 8Nefedova Y, Nagaraj S, Rosenbaner A, et al. Regulation of dendritic cell differentiation and antitumor immune response in eaneer by phar- macologic-selective inhibition of the janus-activated kinase 2/sigual transducers and activators of transcription 3 pathway[ J]. Cancer Res, 2005, 65 ( 20 ) : 9525-9535.
  • 9Nefedova Y, Huang M, Kusmartsev S, et al. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer[J]. J Immuol, 2004, 172(1 ) :464-474.
  • 10梁建明,关有彦,钟永,孙青,戴哲浩,管考鹏,马洁,李长岭,张叔人.膀胱癌患者外周血髓系来源的抑制细胞的比例及其临床意义[J].中国肿瘤临床与康复,2010,17(6):493-497. 被引量：2

二级参考文献13

  • 1Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010[J]. CA Cancer J Clin, 2010,60:277-300.
  • 2Jacobs BL, Lee CT, Montie JE. Bladder cancer in 2010 : how far have we come[J]? CA Cancer J Clin, 2010, 60:244-272.
  • 3Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system[ J]. Nat Rev Immunol, 2009, 9:162-174.
  • 4Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells in human cancer[ J]. Cancer J, 2010, 16:348-353.
  • 5Whiteside TL. Inhibiting the inhibitors: evaluating agents targe- ting cancer inununosuppression [ J ]. Expert Opin Biol Ther, 2010, 10:1019-1035.
  • 6Young MR, Newby M, Wepsic HT. Hematopoiesis and suppres- sor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors[ J]. Cancer Res, 1987, 47 : 100-105.
  • 7Sinha P, Clements VK, Bunt SK, et al. Cross-talk between mye- loid-derived suppressor cells and macrophages subverts tumor im- munity toward a type 2 response[J]. J Immunol, 2007, 179: 977-983.
  • 8Murdoch C, Muthana M, Coffelt SB, et al. The role of myeloid ceils in the promotion of tumour angiogenesis[ J]. Nat Rev Canc- er, 2008, 8:618-631.
  • 9Kusmartsev S, Gabrilovich DI. Inhibition of myeloid cell differ- entiation in cancer: the role of reactive oxygen species [ J]. J Leukoc Biol, 2003, 74 : 186-196.
  • 10Ochoa AC, Zea AH, Hernandez C, et al. Arginase, prostaglan- dins, and myeloid-derived suppressor cells in renal cell carcino- ma[J]. Clin Cancer Res, 2007, 13:721s-726s.

共引文献1

同被引文献32

  • 1Ferrigno D,Buccheri G. Hematologic counts and clinical correlates in 1201 newly diagnosed lung cancer patients[J]. Monaldi Arch Chest Dis, 2003,59(3 ) : 193-198.
  • 2Buergy D, Wenz F, Groden C, et al. Tumor-platelet inter- action in solid tumors[J]. Int J Cancer, 2012, 130(12): 2747 -2760.
  • 3Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis[J]. Nat Rev Cancer,2011, 11 (2):123- 134.
  • 4Martz A, Fur6k J, Varga Z, et al. Thrombocytosis has a neg- ative prognostic value in lung cancer[J]. Anticancer Res, 2013, 33(4) : 1725-1729.
  • 5Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells in human cancer[J] .Cancer, 2010,16(4 ):348-353.
  • 6Iclozan C,Antonia S,Chiappori A,et al.Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer[J].Cancer Immunol Immunother,2013,62:909-918.
  • 7Diaz-Montero CM,Salem ML,Nishimura MI,et al.Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage,metastatic tumor burden,and doxorubicin-cyclophosphamide chemotherapy[J].Cancer Immunol Immunother,2009,58:49-59.
  • 8Rodríguez-Pi珘neiro AM,Blanco-Prieto S,Sanchez-Otero N,et al.On the identification of biomarkers for non-small cell lung cancer in serum and pleural effusion[J].J Proteomics,2010,73:1511-1522.
  • 9Alizadeh D,Larmonier N. Chemotherapeutic targeting of cancerinducedimmunosuppressive cells[J]. Cancer Res,2014,74(10):2663-2668. doi:10.1158 /0008-5472. CAN-14-0301.
  • 10Motz GT,Coukos G. Deciphering and reversing tumor immunesuppression[J]. Immunity,2013,39(1):61-73. doi:10.1016/j.immuni.2013.07.005.

引证文献4

二级引证文献17

中国实用医刊
2013年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部